Page URL:

Illumina sues UK startup over genome-sequencing patents

29 February 2016
Appeared in BioNews 841

The California-based genome-sequencing company Illumina has accused UK rival Oxford Nanopore Technologies of violating its intellectual property rights.

In court papers filed last week, Illumina's lawyers claim that two devices offered by Oxford – MinION, first available in 2014, and the forthcoming PromethION – infringe upon two nanopore-sequencing patents to which the US giant has exclusive licence.

Illumina has also requested that the US International Trade Commission temporarily ban the importation of Oxford's products to the US while further investigation takes place.

The technology in question centres around nanopores – tiny holes within proteins through which DNA molecules can pass. Each of the four DNA bases (A, C, G and T) creates a distinct change in electrical current as it passes through the pore, allowing the genetic code to be read. Oxford's MinION device, which uses this technology, is less reliable than Illumina's refrigerator-sized machines (which use a different type of genome sequencing), but it has the advantage of being small (roughly three inches long), is easily accessible and can generate results in real time.  

Since 2013, Illumina has licensed patents from researchers at the Universities of Washington and Alabama who, in 2010, showed that use of a particular pore known as MspA significantly improves the technology. Illumina claims that it is this pore that is now used by Oxford's devices, arguing that the UK firm has long been interested in the research related to the patents.

The two companies had previously attempted to collaborate on new nanopore technologies. But in 2013 Illumina sold its 13.5 percent share in Oxford, and now claims that its investments and patent rights are under threat from the start-up.

'Illumina has made substantial investments to obtain licenses and develop the nanopore-sequencing technology invented by researchers at the University of Alabama at Birmingham and University of Washington. Illumina filed the lawsuits to protect its investment and patent rights in this technology,' they stated in a press release.

But Oxford say their company was founded on research from the Oxford University lab of Professor Hagan Bayley and they have over 300 patents and patents pending relating to their technologies.

Speculation mounts as to Illumina's motives, and some are of the view that the US firm is trying to stifle its smaller rival or else launch a new nanopore-sequencing tool of its own.

Mick Watson, a researcher at the University of Edinburgh, has pointed to the timing of this legal action, with Oxford planning to float on the stock market later this year. He has also questioned the applicability of Illumina's patents, given the significant modifications Oxford Nanopore have likely made to the pores over the past few years.

Oxford have remained unwilling to explain precisely how its nanopore technology works. However, in a press release on the company's website, CEO Dr Gordon Sanghera remarked: 'It is gratifying to have the commercial relevance of Oxford Nanopore products so publicly acknowledged by the market monopolist for NGS [next generation sequencing].'

According to MIT Technology Review, the outcome of the legal action could have ramifications on scientific research, as nanopore-sequencing is being used by researchers in increasingly diverse ways. For example, the device has recently been used by researchers in Guinea to sequence the Ebola virus.

Illumina have not announced any plans to launch their own nanopore-sequencing device, but their lawyers claim that they could 'fill any void' created by blocking imports of Oxford's products.

Oxford said it did not expect disruption to its 'commercial progress' from Illumina's legal action.

Illumina, Inc., University of Washington and UAB Research Foundation vs Oxford Nanopore Technologies Ltd. and Oxford Nanopore Technologies Inc.
US District Court Southern District of California |  23 February 2016
Illumina Sues Oxford Nanopore for Patent Infringement
GenomeWeb |  23 February 2016
Illumina Sues Oxford Nanopore for Patent Infringement
Illumina (press release) |  23 February 2016
Illumina Sues Oxford Nanopore Technologies Over Composition of Nanopores
BioITWorld |  24 February 2016
Response to litigation
Oxford Nanopore (press release) |  24 February 2016
Shots fired – nanopore wars part II
Opiniomics (Blog) |  24 February 2016
With Patent Suit, Illumina Looks to Tame Emerging British Rival Oxford Nanopore
MIT Technology Review |  24 February 2016
27 November 2017 - by Dr Rachel Montgomery 
The UK Patents Court has ruled that two separate non-invasive prenatal tests infringe patents licensed by the US firm Illumina...
16 May 2016 - by Sarah Gregory 
Researchers have developed a quick and cheap 'paper-based' test that uses CRISPR to detect the Zika virus...
20 October 2014 - by Sean Byrne 
Illumina has announced the first three companies in its Accelerator Programme, designed to help genomics start-ups as other sources of funding grow scarce...
26 August 2014 - by Dr Molly Godfrey 
The DNA sequencing company Illumina have announced collaborations with three major pharmaceutical companies - AstraZeneca, Sanofi and Johnson & Johnson - to develop a single test for several gene mutations in cancer...
4 August 2014 - by Siobhan Chan 
The UK Government has announced it will provide £300 million funding for a project to sequence 100,000 genomes, saying that it will 'revolutionise [the] fight against cancer and rare diseases'...
20 January 2014 - by Dr Rachael Panizzo 
The $1,000 genome may have arrived, an achievement which would mark a significant milestone in the application of genetic science...
27 February 2012 - by Ayesha Jadoon 
A handheld device for sequencing DNA on the move has been unveiled by UK company Oxford Nanopore. The single-use MinION tool resembles a USB drive in size and shape, and the company hopes it will be put into routine use by clinicians and researchers alike...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.